| Today’s Big NewsJan 3, 2025 |
| By Nick Paul Taylor Will 2025 be better? After another tough year, the answer to that question will shape the prospects of innumerable drug candidates and the lives of people who work in biotech. Evaluate analysts made predictions in their 2025 preview—and anyone expecting a dramatic turnaround should look away now. |
|
|
|
By Gabrielle Masson Regeneron has scooped up Oxular, a retinal-disease-focused company based in the U.K., closing the deal at the very end of 2024. |
By James Waldron iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin antibody that it hopes can induce weight loss while retaining muscle mass. |
By James Waldron Investor David Lazar has come to the rescue of cash-strapped Cyclacel Pharmaceuticals, pumping $3 million into the biotech as well as taking on the top role and shaking up the board. |
By Darren Incorvaia,Zoey Becker After being acquired by clinical-stage ADC company Oqory, Vincerx ended 2024 with a workforce reduction and C-suite clear-out that will involve Ahmed Hamdy, M.D., stepping down as CEO, while remaining as chairman. |
By Darren Incorvaia An investigational drug for multiple sclerosis from Io Therapeutics has restored leg mobility and myelin nerve coatings in mice, the biotech announced Dec. 23. |
By Fraiser Kansteiner After plugging $23 billion into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking to wade into a lawsuit that could allow compounding pharmacies to continue churning out the popular diabetes and obesity drugs. |
By Conor Hale This year may bring major changes in how artificial intelligence shapes the healthcare industry—and vice versa—and tempering hype for the technology with ensuring patient safety will be essential. |
By Angus Liu More than three years after Novartis’ plan for a speedy approval for its intrathecal Zolgensma was thwarted by an FDA requirement for a phase 3 trial, the company is back with a positive readout from that study, which could give the gene therapy a much-needed boost. |
Fierce podcastsDon’t miss an episode |
| | This week on "Podnosis," we explore how teaching kids social-emotional skills early can transform their lifelong wellbeing. |
|
|---|
|
|
| |
|
